Research

Attention Researchers! GBS Deemed Eligible for Research Studies through Department of Defense Peer Review

In March 2018 Congress passed an omnibus bill that finalized Fiscal Year 2018 appropriations. Guillain-Barré Syndrome was again listed as a condition eligible for study! Now is the time to begin applications for available grants. Below is more detailed information regarding applications and possible awards.

Read More about Attention Researchers! GBS Deemed Eligible for Research Studies through Department of Defense Peer Review

FDA approves CSL Behring treatment for CIDP

The Food and Drug Administration granted marketing clearance Friday for Hizentra, a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) developed by CSL Behring.  Lisa Butler, executive director of the GBS/CIDP Foundation International, said “The approval of Hizentra offers patients who were once burdened by traveling to the infusion center or hospital the flexibility to self-administer their treatment at…

Read More about FDA approves CSL Behring treatment for CIDP